CLAIMS

1. Use of a triptan in the preparation of a medicament for ~~A method of treating~~ the treatment of symptoms associated with autism spectrum disorder (ASD) ~~comprising administering a therapeutically effective amount of a triptan to~~ in a patient ~~in need thereof~~.
2. The ~~method~~ use of claim 1, wherein prior to said treatment the patient is diagnosed with ASD using the DSM-5 diagnostic criteria.
3. The ~~method~~ use of any one of claims 1-2, wherein prior to said treatment the patient's Aberrant Behavior Checklist Irritability Subscale (ABC-I) score is ≥ 18.
4. The ~~method~~ use of any one of claims 1-3, wherein prior to said treatment the patient's Social Responsiveness Scale, 2nd Edition (SRS-2), proxy version total t-score is ≥ 66.
5. The ~~method~~ use of any one of claims 1-4, wherein prior to said treatment the patient's full scale IQ score on the Wechsler Abbreviated Scale of Intelligence (WASI®)-II is ≥ 70.
6. The ~~method~~ use of any one of claims 1-5, wherein prior to the treatment the patient has severe irritability and/or aggression.
7. The ~~method~~ use of any one of claims 1-6, wherein prior to the treatment the patient has moderate irritability and/or aggression.
8. The ~~method~~ use of any one of claims 1-7, wherein prior to the treatment the patient has moderate lethargy and/or social deficits.
9. The ~~method~~ use of any one of claims 1-8, wherein patient's symptoms are refractory to treatment with aripiprazole and risperidone.
10. The ~~method~~ use of any one of claims 1-9, wherein the patient is an adolescent.
11. The ~~method~~ use of any one of claims 1-9, wherein the patient is a child.
12. The ~~method~~ use of any one of claims 1-9, wherein the patient is an adult.
13. The ~~method~~ use of any one of claims 1-12, wherein the triptan is selected from the group consisting of sumatriptan, zolmitriptan, naratriptan, rizatriptan, almotriptan, frovatriptan, eletriptan, donitriptan and avitriptan or a pharmaceutically acceptable salt thereof.
14. The ~~method~~ use of any one of claims 1-13, wherein the triptan is zolmitriptan or a pharmaceutically acceptable salt thereof.

15. The ~~method~~ use of any one of claim 1-14, wherein after said ~~treating~~ treatment the patient experiences a substantial reduction in the symptoms associated with ASD compared to prior to said treating.
16. The ~~method~~ use of any of claims 1-15, wherein after said ~~treating~~ treatment the patient experiences a substantial improvement in sociability compared to prior to said treating.
17. The ~~method~~ use of any one of claims 1-16, wherein after said ~~treating~~ treatment the patient experiences an improvement in sociability that is characterized by an at least 10% decrease in the sociability subsection of the ATEC compared to prior to the treatment.
18. The ~~method~~ use of any one of claims 1-17, wherein after said ~~treating~~ treatment the patient experiences an improvement in sociability that is characterized by an at least 10% decrease in the social reciprocity score on the Autism Diagnostic Observation Schedule module 4 compared to prior to the treatment.
19. The ~~method~~ use of any one of claims 1-18, wherein after said ~~treating~~ treatment the patient experiences an improvement in sociability that is characterized by an at least 10% decrease in SRS-A score compared to prior to the treatment.
20. The ~~method~~ use of any one of claims 1-19, wherein after said ~~treating~~ treatment the patient experiences an improvement in sociability associated with ASD that is characterized by a Clinical Global Impression−Change (CGI-C) score of ≤ 3.
21. The ~~method~~ use of any of claims 1-20, wherein after said ~~treating~~ treatment the patient experiences a substantial decrease in irritability associated with ASD compared to prior to said ~~treating~~treatment.
22. The ~~method~~ use of any one of claims 1-21, wherein after said ~~treating~~ treatment the patient experiences an improvement in irritability associated with ASD that is characterized by an at least 10% decrease in ABC-I score compared to prior to the treatment.
23. The ~~method~~ use of any one of claims 1-22, wherein after said ~~treating~~ treatment the patient experiences an improvement in irritability associated with ASD that is characterized by an at least 35% decrease in ABC-I score compared to prior to the treatment.
24. The ~~method~~ use of any one of claims 1-23, wherein after said ~~treating~~ treatment the patient experiences an improvement in irritability associated with ASD that is characterized by a Clinical Global Impression−Change (CGI-C) score of ≤ 3.

25. The ~~method~~ use of any one of claims 1-24, wherein after said ~~treating~~ treatment the patient experiences an improvement in symptoms of ASD that is characterized by an at least 10% improvement in the socialization domain score of the Vineland 3 Adaptive Behavior Scale compared to prior to the treatment.
26. The ~~method~~ use of any one of claims 1-25, wherein after said ~~treating~~ treatment the patient experiences an improvement in symptoms of ASD that is characterized by a characterized by an at least 10% improvement in the communication domain score of the Vineland 3 Adaptive Behavior Scale compared to prior to the treatment.
27. The ~~method~~ use of any one of claims 1-26, wherein after said ~~treating~~ treatment the patient experiences an improvement in symptoms of ASD that is characterized by an at least one point improvement in Autism Diagnostic Observation Schedule, Second Edition (ADOS-2) Composite Total score compared to prior to the treatment.
28. The ~~method~~ use of any one of claims 1-27, wherein after said ~~treating~~ treatment the patient experiences an improvement in symptoms of ASD that is characterized by an at least one point decrease in OARS-5 Total Score compared to prior to the treatment.
29. The ~~method~~ use of any one of claims 1-28, wherein after said ~~treating~~ treatment the patient experiences an improvement in symptoms of ASD that is characterized by an at least one point decrease in OARS-5 Social Deficits Subscale Score compared to prior to the treatment.
30. The ~~method~~ use of any one of claims 1-29, wherein after said ~~treating~~ treatment the patient experiences an improvement in symptoms of ASD that is characterized by an at least one point decrease in OSU Autism CGI total score compared to prior to the treatment.
31. The ~~method~~ use of any one of claims 1-30, wherein after said ~~treating~~ treatment the patient experiences an improvement in symptoms of ASD that is characterized by an at least one point decrease in OSU Autism CGI-I score compared to prior to the treatment.
32. The ~~method~~ use of any one of claims 1-31, wherein after said ~~treating~~ treatment the patient experiences an improvement in symptoms of ASD that is characterized by an at least one point decrease in OSU Autism CGI-S score compared to prior to the treatment.